I think we all want to see that trial start. I guess it will be done at the Florey. I was just repeating what they published. "This finding raises the possibility that CSF α-synuclein may be of value as a marker of target engagement in the clinical setting." "may be judiciously applied to the evaluation of target engagement for new drugs, assisting in the early phases of clinical development"
That publication is almost a year old. I would like to see it included, but as we know what is demonstrated in dogs may not be the same in humans.
PBT Price at posting:
4.5¢ Sentiment: Buy Disclosure: Held
